Table 1

Efficacy of temozolomide in neuroblastoma xenograft models

TumorTreatment (mg/kg)No. in groupAverage week tumor achieved 4× initial tumor volume (±1 SD)Tumor growth delay (weeks)Adjusted PaNo. of PRsNo. of CRsMCRbTime to reach nadir (weeks)cTime to recover to initial tumor volume (weeks)d
NB-EBControl71.8 ± 0.800
6677.8 ± 2.86.00.00334125
NB-1771Control62.8 ± 1.000
667>12>9.20.0010774>12
NB-1382Control72.1 ± 0.400
667>12>9.90.0010772>12
NB-1643Control73.2 ± 1.000
667>12>8.80.0010753>12
NB-1691Control72.4 ± 1.000
6662.8 ± 0.50.40.2121012
NB-1691Control74.7 ± 2.600
6679.0 ± 1.74.30.0055026
NB-SDControl73.3 ± 1.400
667>12>8.70.001311911
  • a Ps were obtained using exact log-rank tests (with Bonferroni correction procedure). Ps compare tumor failure times among treatment groups and respective control group.

  • b Number of CRs maintained through week 12.

  • c Mean nadir for all tumors after start of treatment.

  • d Time for mean recovery to initial treatment volume.